Calliditas Therapeutics AB (publ) (CLTEF)
CLTEF Stock Price Chart
Explore Calliditas Therapeutics AB (publ) interactive price chart. Choose custom timeframes to analyze CLTEF price movements and trends.
CLTEF Company Profile
Discover essential business fundamentals and corporate details for Calliditas Therapeutics AB (publ) (CLTEF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Sept 2020
Employees
178.00
Website
https://www.calliditas.seCEO
Renee Aguiar-Lucander
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
CLTEF Financial Timeline
Browse a chronological timeline of Calliditas Therapeutics AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 30 Sept 2023
EPS came in at -$0.03 , while revenue for the quarter reached $2.45M .
Earnings released on 30 Jun 2023
EPS came in at -$0.01 , while revenue for the quarter reached $2.30M .
Earnings released on 31 Mar 2023
EPS came in at -$0.03 , while revenue for the quarter reached $1.77M .
Earnings released on 23 Feb 2023
EPS came in at -$0.07 surpassing the estimated -$1.71 by +95.91%, while revenue for the quarter reached $4.02M .
Earnings released on 14 Nov 2022
EPS came in at -$0.17 surpassing the estimated -$3.02 by +94.37%, while revenue for the quarter reached $2.09M .
Earnings released on 18 Aug 2022
EPS came in at -$3.62 surpassing the estimated -$4.23 by +14.42%, while revenue for the quarter reached $608.54K .
Earnings released on 18 May 2022
EPS came in at -$3.95 , while revenue for the quarter reached $563.63K .
Earnings released on 24 Feb 2022
EPS came in at -$4.19 falling short of the estimated -$3.72 by -12.63%, while revenue for the quarter reached $379.94K .
Earnings released on 18 Nov 2021
EPS came in at $0.21 , while revenue for the quarter reached $2.58M .
Earnings released on 19 Aug 2021
EPS came in at -$3.20 .
Earnings released on 18 May 2021
EPS came in at -$2.51 .
Earnings released on 18 Feb 2021
EPS came in at -$0.05 , while revenue for the quarter reached $5.90K .
Earnings released on 12 Nov 2020
EPS came in at -$0.03 .
CLTEF Stock Performance
Access detailed CLTEF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.